Acrivon Therapeutics, Inc.
ACRVFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Acrivon Therapeutics, Inc. Makes Money
No flow chart is shown because the available revenue and expense lines do not reconcile exactly. The reported financial history below remains available.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 5 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 22, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| DIMENSIONAL FUND ADVISORS LP | 2026-03-31 | 18,364 | $25.4K | SEC filing |
| Caitong International Asset Management Co., Ltd | 2026-03-31 | 4 | $6 | SEC filing |
| GSA CAPITAL PARTNERS LLP | 2026-03-31 | 186,716 | Not shown | SEC filing |
| WELLINGTON MANAGEMENT GROUP LLP | 2026-03-31 | 888,130 | $1.23M | SEC filing |
| TWO SIGMA SECURITIES, LLC | 2026-03-31 | 11,679 | $16.2K | SEC filing |
| RA CAPITAL MANAGEMENT, L.P. | 2026-03-31 | 8,340,508 | $11.6M | SEC filing |
| BNP PARIBAS FINANCIAL MARKETS | 2026-03-31 | 634 | $881 | SEC filing |
| BARCLAYS PLC | 2026-03-31 | 5,940 | $8.26K | SEC filing |
| PRELUDE CAPITAL MANAGEMENT, LLC | 2026-03-31 | 24,015 | $33.4K | SEC filing |
| Federation des caisses Desjardins du Quebec | 2026-03-31 | 400 | $556 | SEC filing |
| NISA INVESTMENT ADVISORS, LLC | 2026-03-31 | 584 | $812 | SEC filing |
| XTX Topco Ltd | 2026-03-31 | 66,882 | $93K | SEC filing |
| Sands Capital Alternatives, LLC | 2026-03-31 | 2,122,605 | $2.95M | SEC filing |
| JPMORGAN CHASE & CO | 2026-03-31 | 638 | $823 | SEC filing |
| UBS Group AG | 2026-03-31 | 34,634 | $48.1K | SEC filing |
| GEODE CAPITAL MANAGEMENT, LLC | 2026-03-31 | 236,391 | $329K | SEC filing |
| NORTHERN TRUST CORP | 2026-03-31 | 48,902 | $68K | SEC filing |
| TWO SIGMA INVESTMENTS, LP | 2026-03-31 | 389,395 | $541K | SEC filing |
| RENAISSANCE TECHNOLOGIES LLC | 2026-03-31 | 758,440 | $1.05M | SEC filing |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 2026-03-31 | 158,900 | $221K | SEC filing |
- Each value is checked against Acrivon Therapeutics, Inc.'s share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 1 row: the filed value is about 1,000 times too small for the share count at Acrivon Therapeutics, Inc.'s share price.
Filer report history
Two reports per filer, as filed. No change is calculated, because the data on file cannot confirm that both reports describe the same security.
- MARSHALL WACE, LLP: 496,081 shares reported 2025-12-31; 560,436 shares reported 2026-03-31.
- BANK OF AMERICA CORP /DE/: 17,447 shares reported 2025-12-31; 16,513 shares reported 2026-03-31.
- Marex Group plc: 10,000 shares reported 2025-12-31; 20,000 shares reported 2026-03-31.
- Russell Investments Group, Ltd.: 481 shares reported 2025-12-31; 481 shares reported 2026-03-31.
- BlackRock, Inc.: 205,124 shares reported 2025-12-31; 208,939 shares reported 2026-03-31.
- ACADIAN ASSET MANAGEMENT LLC: 581,208 shares reported 2025-12-31; 845,973 shares reported 2026-03-31.
- AAF Wealth Management, LLC: 10,678 shares reported 2025-12-31; 10,678 shares reported 2026-03-31.
- SBI Securities Co., Ltd.: 74 shares reported 2025-12-31; 74 shares reported 2026-03-31.
- Squarepoint Ops LLC: 26,162 shares reported 2025-12-31; 27,472 shares reported 2026-03-31.
- STATE STREET CORP: 67,145 shares reported 2025-12-31; 67,145 shares reported 2026-03-31.
- FMR LLC: 8,622 shares reported 2025-12-31; 9,422 shares reported 2026-03-31.
- JANE STREET GROUP, LLC: 342,071 shares reported 2025-12-31; 239,691 shares reported 2026-03-31.
Showing the 12 most recent filer reports.
16 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Acrivon Therapeutics, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2025-04-25 · EDELMAN JOSEPH: Larger than all 9 other insider sales of Common Stock on file. SEC filing
Independent insiders buying near the same time
- 2026-01-13–2026-01-14: 3 event(s) across 3 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing )
- 2022-11-17–2022-11-17: 2 event(s) across 2 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing )
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-01-14 | Levy Adam D. · Chief Financial Officer | Common Stock | P — Open market or private purchase | +8,832 | 1.70 | SEC filing |
| 2026-01-14 | Blume-Jensen Peter · President and CEO | Common Stock | P — Open market or private purchase | +49,000 | 1.68 | SEC filing |
| 2026-01-13 | Devroe Eric · Chief Operating Officer | Common Stock | P — Open market or private purchase | +10,000 | 1.72 | SEC filing |
| 2025-05-01 | EDELMAN JOSEPH · 10% owner | Common Stock | S — Open market or private sale | −298,886 | 1.34 | SEC filing |
| 2025-04-30 | EDELMAN JOSEPH · 10% owner | Common Stock | S — Open market or private sale | −437,881 | 1.41 | SEC filing |
| 2025-04-29 | EDELMAN JOSEPH · 10% owner | Common Stock | S — Open market or private sale | −250,000 | 1.41 | SEC filing |
| 2025-04-28 | EDELMAN JOSEPH · 10% owner | Common Stock | S — Open market or private sale | −215,283 | 1.56 | SEC filing |
| 2025-04-25 | EDELMAN JOSEPH · 10% owner | Common Stock | S — Open market or private sale | −1,054,669 | 1.95 | SEC filing |
Showing 8 of 16 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-17 | DiRocco Derek · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +20,275 | SEC filing |
| 2026-06-17 | TOMSICEK MICHAEL JOHN · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +20,275 | SEC filing |
| 2026-06-17 | Magovcevic-Liebisch Ivana · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +20,275 | SEC filing |
| 2026-06-17 | Shacham Sharon · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +20,275 | SEC filing |
| 2026-06-17 | Palani Santhosh · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +20,275 | SEC filing |
| 2026-06-17 | BAUM CHARLES M · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +20,275 | SEC filing |
| 2026-06-17 | RA Capital Healthcare Fund LP · Director, 10% owner | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +20,275 | SEC filing |
| 2026-05-21 | Blume-Jensen Peter · President and CEO | Common Stock | F — Payment of exercise price or tax by delivering securities | −13,729 | SEC filing |
Showing 8 of 30 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.